New drug hopes to shrink tumors in patients out of options

NCT ID NCT07306559

Recruiting now Disease control Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 06, 2026 · Updated 8 times

Summary

This study tests a new drug called BI 3820768 in adults with advanced germ cell tumors, endometrial cancer, or ovarian cancer who have run out of treatment options. The drug aims to help the immune system fight cancer. Researchers will give increasing doses to find a safe amount that may shrink tumors. Participants receive weekly injections for 6 weeks, then every 3 weeks, and are followed for up to 3 years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BI 3820768
What this could lead to: If this works, it could point toward a new treatment option for people with advanced cancers that have not responded to other therapies.
What could go wrong: This is a very early Phase 1 trial, so the drug may not work or may cause serious side effects. It is the first time this drug is tested in humans, so success is uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED RELAPSED OR REFRACTORY ENDOMETRIAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometrial cancer endometrial carcinoma endometrium neoplasm germ cell tumor malignant testicular germ cell tumor ovarian cancer ovarian carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED RELAPSED OR REFRACTORY ENDOMETRIAL CANCER ADVANCED RELAPSED OR REFRACTORY GERM CELL TUMOURS ADVANCED RELAPSED OR REFRACTORY OVARIAN CANCER

Contacts and locations

Locations

Cliniques Universitaires Saint-Luc
RECRUITING

Brussels, 1200, Belgium
Clínica Universidad de Navarra - Madrid
RECRUITING

Madrid, 28027, Spain
Hospital Universitari Vall d'Hebron
RECRUITING

Barcelona, 08035, Spain
INS Paoli-Calmettes
RECRUITING

Marseille, 13009, France
Indiana University
NOT_YET_RECRUITING

Indianapolis, Indiana, 46202, United States
Institut Gustave Roussy
RECRUITING

Villejuif, 94800, France
Japanese Foundation for Cancer Research
RECRUITING

Tokyo, Koto-ku, 135-8550, Japan
Klinikum der Universität München AÖR
RECRUITING

München, 81377, Germany
National Cancer Center Hospital East
RECRUITING

Chiba, Kashiwa, 277-8577, Japan
The University of Texas MD Anderson Cancer Center
NOT_YET_RECRUITING

Houston, Texas, 77030, United States
UZ Leuven
SUSPENDED

Leuven, 3000, Belgium
Universitätsklinikum Würzburg AÖR
RECRUITING

Würzburg, 97078, Germany
Valkyrie Clinical Trials
RECRUITING

Los Angeles, California, 90067, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.